Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment
- 1 December 2023
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 134 (6) , 2602-2608
Abstract
Objectives: Ocular surface reactions (OSR) have been associated with dupilumab for atopic dermatitis (AD) treatment. However, the association of dupilumab‐associated OSR (DA‐OSR) for nasal polyps (CRSwNP) treatment has not been studied. We evaluated DA‐OSR for CRSwNP treatment using the FDA Adverse Event Reporting System (FAERS). Methods: FAERS was queried for any general ocular reactions (DA‐GOR) from 2019Q1 to 2022Q4. DA‐OSR were subcategorized from DA‐GOR and compared between treatment groups (CRSwNP, asthma, AD). Logistic regression was used to predict DA‐OSR. Disproportionality analysis (DPA) of DA‐OSR was performed using OpenVigil. Results: There were 60,198 total observations, of which 5344 were treated for CRSwNP. The prevalence of DA‐GOR and DA‐OSR was greatest for AD (15.3%, 7.8%), followed by CRSwNP (12.2%, 6.7%) and asthma (9.2%, 3.5%). The most commonly reported OSRs were dry eyes (35.9%), conjunctivitis (15.7%), and increased lacrimation (11.0%). The reported odds ratio (ROR) of CRSwNP‐treated DA‐OSR was 0.84 (0.73–0.97; p = 0.015), compared to 1.29 (1.20–1.40; p < 0.001) for AD and 0.66 (0.59–0.73; p < 0.001) for asthma. For CRSwNP treatment, the DA‐OSR ROR was 0.97 (0.90–1.03; p = 0.3) for men and 0.78 (0.73–0.83, p < 0.001) for older adults (age > 50). ROR in the DPA for DA‐OSR was 12.5 (12.2–12.8; p < 0.001) for any indication and 0.58 (0.53–0.64; p < 0.001) for CRSwNP treatment only. Conclusions: While there are limitations to FAERS, this study confirms the association between dupilumab and OSR for AD treatment, and does not support an association between dupilumab and OSR for CRSwNP treatment. Younger adults experience more DA‐OSR in CRSwNP treatment without a specific predilection for sex. Level of Evidence: IV Laryngoscope , 134:2602–2608, 2024Keywords
This publication has 52 references indexed in Scilit:
- Cicatricial ectropion in a patient treated with dupilumabAmerican Journal of Ophthalmology Case Reports, 2017
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitisJournal of the American Academy of Dermatology, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2017
- OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical ApplicationsPLOS ONE, 2016
- Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkersJournal of Allergy and Clinical Immunology, 2016
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal PolyposisJAMA, 2016
- Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilanceChinese Journal of Natural Medicines, 2013
- Data Mining of the Public Version of the FDA Adverse Event Reporting SystemInternational Journal of Medical Sciences, 2013
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001